# US 2004/0018207 A1 · Preventive and therapeutic AIDS vaccines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0018207 A1
- Document ID: US20040018207A1
- Status: Published application
- Kind: A1
- Application number: 10/207,346
- Filed: 2002-07-29
- Published: 2004-01-29
- Earliest claimed: 2002-07-29
- Inventors: Qun Chen
- Web page: https://patentgrep.com/patent/US20040018207A1

## CPC

- C07K 14/005: from viruses
- A61K 39/12: Viral antigens
- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- A61K 2039/5258: {Virus-like particles}
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C12N 2740/16034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16043: viral genome or elements thereof as genetic vector
- C12N 2740/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16322: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/16334: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to prophylactic and therapeutic acquired immunodeficiency syndrome vaccines. In particular, the present invention provides methods and compositions utilizing recombinant HIV-1, HIV-2 and/or SIV genes or gene products in safe vaccination approaches.

## Claims

### Claim 1

A method for administering a vaccine to a subject, comprising the steps of:
a. providing a subject, and at least three subunit vaccines, wherein said vaccines together but not individually comprise a complete immunodeficiency virus genome encoding viral Gag, Pol, Env, regulatory and accessory proteins, in the absence of immunodeficiency virus long terminal repeats; and
b. administering said vaccines to said subject under conditions suitable for inducing an immune response against said viral Gag, Pol, Env, regulatory and accessory proteins.

### Claim 2 (depends on 1)

The method of claim 1, wherein said subject is selected from the group consisting of an adult, a youth, and a neonate.

### Claim 3 (depends on 1)

The method of claim 1, wherein said subject is a mammal selected from the group consisting of a human, a nonhuman primate, a horse, a cow, a sheep, a rodent, a goat and a cat.

### Claim 4 (depends on 1)

The method of claim 1, wherein said subject is selected from the group consisting of an immunodeficiency virus infected subject and a subject uninfected with an immunodeficiency virus.

### Claim 5 (depends on 1)

The method of claim 1, wherein said administering is done through at least one route selected from the group consisting of intramuscular, intravenous, intraperitoneal, subcutaneous, oral, intranasal, intravaginal, intrarectal, and stomacheal.

### Claim 6 (depends on 1)

The method of claim 1, wherein said vaccines are administered in a physiologically acceptable solution.

### Claim 7 (depends on 1)

The method of claim 1, wherein said immune response comprises antibodies reactive with said viral Gag, Pol, Env, regulatory and accessory proteins.

### Claim 8 (depends on 1)

The method of claim 1, wherein said immune response comprises cytotoxic T lymphocytes reactive with said viral Gag, Pol, Env, regulatory and accessory proteins.

### Claim 9 (depends on 1)

The method of claim 1, wherein said immune response comprises helper T lymphocytes reactive with said viral Gag, Pol, Env, regulatory and accessory proteins.

### Claim 10 (depends on 1)

The method of claim 1, wherein said at least three vaccines comprise a first vaccine, a second vaccine, and a third vaccine, and wherein said second vaccine is administered after said first vaccine has induced an immune response, and said third vaccine is administered after said second vaccine has induced an immune response.

### Claim 11

A method for producing a set of at least three subunit vaccines comprising the steps of:
a. cloning genes of at least one immunodeficiency virus;
b. mutating at least one of said genes;
c. constructing a library by ligating said genes individually or in combination into at least one vector; and
d. classifying members of said library into a set of at least three subunit vaccines, wherein said vaccines together but not individually comprise a complete immunodeficiency virus genome encoding viral Gag, Pol, Env, regulatory and accessory proteins, in the absence of immunodeficiency virus long terminal repeats.

### Claim 12 (depends on 11)

The method of claim 11, wherein said immunodeficiency virus is selected from the group consisting of HIV-1, HIV-2, SIV, and SHIV.

### Claim 13 (depends on 12)

The method of claim 12, wherein said at least one immunodeficiency virus genome further comprises at least one gene derived from a distinct immunodeficiency virus.

### Claim 14 (depends on 11)

The method of claim 11, wherein said at least one vector is selected derived from the group consisting of a plasmid vector, an artificial chromosome vector, a bacterial vector, a fungal vector, and a viral vector.

### Claim 15 (depends on 11)

The method of claim 11, wherein said mutating comprises introduction of at least one mutation into the active site of a viral Pol protein selected from the group consisting of protease, reverse transcriptase, RNase H and integrase.

### Claim 16 (depends on 11)

The method of claim 11, wherein at least one of said subunit vaccines further comprises a pharmaceutically suitable carrier.

### Claim 17 (depends on 11)

The method of claim 11, wherein at least one of said subunit vaccines further comprise at least one molecular adjuvant selected from the group consisting of a co-stimulatory molecule, a cytokine, a chemokine and a growth factor.

### Claim 18 (depends on 11)

The method of claim 11, wherein said set of at least three subunit vaccines is suitable for production of a pseudoviral particle comprising structural, regulatory and accessory proteins from said immunodeficiency virus.

### Claim 19 (depends on 18)

The method of claim 18, wherein said pseudoviral particle comprises said immunodeficiency virus gag gene, in the absence of said immunodeficiency virus env gene.

### Claim 20 (depends on 19)

The method of claim 19, wherein said pseudoviral particle is incapable of producing viral progeny.

### Claim 21

A composition comprising at least three subunit vaccines, wherein said subunit vaccines together but not individually comprise a complete immunodeficiency virus genome encoding viral Gag, Pol, Env, regulator and accessory proteins, in the absence of immunodeficiency virus long terminal repeats.

### Claim 22 (depends on 21)

The composition of claim 21, wherein said immunodeficiency virus is selected from the group consisting of HIV-1, HIV-2, SIV, and SHIV.

### Claim 23 (depends on 21)

The composition of claim 21, wherein said at least one immunodeficiency virus genome further comprises at least one gene derived from a distinct immunodeficiency virus.

### Claim 24 (depends on 21)

The composition of claim 21, wherein said at least three subunit vaccines comprise at least one vector selected from the group consisting of a plasmid vector, an artificial chromosome vector, a bacterial vector, a fungal vector, and a viral vector.

### Claim 25 (depends on 21)

The composition of claim 21, wherein at least one of said viral Pol proteins bears a mutation in its active site.

### Claim 26 (depends on 21)

The composition of claim 21, wherein at least one of said subunit vaccines further comprises a pharmaceutically suitable carrier.

### Claim 27 (depends on 21)

The composition of claim 21, wherein at least one of said subunit vaccines further comprise at least one molecular adjuvant selected from the group consisting of a co-stimulatory molecule, a cytokine, a chemokine and a growth factor.

### Claim 28 (depends on 21)

The composition of claim 21, wherein said at least three subunit vaccines are suitable for production of a pseudoviral particle comprising structural, regulatory and accessory proteins from said immunodeficiency virus.

### Claim 29 (depends on 28)

The composition of claim 28, wherein said pseudoviral particle comprises said immunodeficiency virus gag gene, in the absence of said immunodeficiency virus env gene.

### Claim 30 (depends on 29)

The composition of claim 29, wherein said pseudoviral particle is incapable of producing viral progeny.
